Literature DB >> 10387965

Adjuvant Chemotherapy of Colorectal Cancer.

.   

Abstract

Advances have been made in the adjuvant therapy of colorectal cancers. Fluorouracil-based chemotherapy has now been demonstrated to improve long-term disease-free survival rates in patients with resected stage III colon cancer. Combined radiation therapy plus fluorouracil-based chemotherapy has been shown to improve both local control and disease-free survival in patients with stage II and III rectal cancer. In this article we will review in detail the current recommendations for treatment of patients with resected colorectal cancers and the data on which these recommendations are based. We will also review some of the more promising investigational approaches which are being pursued in an attempt to further improve the cure rates in patients with local-regionally advanced colorectal cancers. Results from these investigations can be expected to further clarify the role of both currently available and new treatment strategies, and to improve the long-term outlook for patients with resectable colorectal cancers.

Entities:  

Year:  1996        PMID: 10387965

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  3 in total

1.  Use of Adjuvant Chemotherapy among Stage II Colon Cancer Patients in 10 Population-Based National Program of Cancer Registries.

Authors:  Christie R Eheman; Mary Elizabeth O'Neil; Timothy S Styles; Trevor D Thompson; Cyllene R Morris; Frances A Babcock; Vivien W Chen
Journal:  J Registry Manag       Date:  2016

2.  Superiority of combined chemo-embolization and portal infusion with 5-fluorouracil over locoregional infusion concepts in Novikoff hepatoma-bearing rats.

Authors:  Hermann Bödeker; Ernst-Jan Kamphorst; Peter H Wünsch; Ulrich Linnemann; Martin R Berger
Journal:  J Cancer Res Clin Oncol       Date:  2003-09-26       Impact factor: 4.553

3.  Disparate Response to Methotrexate in Stem Versus Non-Stem Cells.

Authors:  Olivia S Beane; Louise E O Darling; Vera C Fonseca; Eric M Darling
Journal:  Stem Cell Rev Rep       Date:  2016-06       Impact factor: 5.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.